The linkage between psoriasis and non-alcoholic fatty liver disease: A literature review

Acta Dermatovenerologica Croatica

Volumn 22, Issue 2, 2014, Pages 132-136

  Ramos, Andréia Nogueira ^a   Rocha, Bruno de Oliveira ^a   Rêgo, Vitória Regina Pedreira de Almeida ^a   Follador, Ivonise ^a   de Oliveira, Maria de Fátima Santos Paim ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Non alcoholic fatty liver disease; Psoriasis; Steatohepatitis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HLA B ANTIGEN; HLA B13 ANTIGEN; HLA B17 ANTIGEN; HLA BW57 ANTIGEN; HLA C ANTIGEN; HLA CW6 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FAT INTAKE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HYPERTRANSAMINASEMIA; INNATE IMMUNITY; INSULIN RESISTANCE; LEUKOCYTE MIGRATION; LIVER FIBROSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; T LYMPHOCYTE ACTIVATION; COMPLICATION; INFLAMMATION; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

HUMANS; INFLAMMATION; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84905100263     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Christophers, E. Psoriasis epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
2. Schön MP, Boehncke, WH. Psoriasis. N Engl J Med 2005;352:1899-912.
3. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clinics in Dermatol 2007;25:510-8.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
5. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol 2004;50:4
6. Davidovici BB, Sattar N, Prinz JC, Jörg PC, Puig L, Emery P, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-96.
7. Gisondi P, Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr 2009;100 (SUPPL 2):1421.
8. Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003;17:1-5.
9. Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermosifiliogr 2010;101:657-8.
10. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol 2011;146:9-15.
11. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol 2009;51:75864.
12. Farrel GC, Larter CZ. Non-alcoholic fatty liver disease: From steatosis to cirrhosis. Hepatol 2006;43: S99-S112.
13. Paschos P, Paleta K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;13:9-19.
14. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010;18:297-304.
15. Karnikowiski M, Córdova C, Oliveira RJ, Karnikowski MGO, Nóbrega OT,. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian median-aged and older adults. Sao Paulo Med J 2007;125:333-7.
16. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33.
17. Bitencourt AGV, Cotrim HP, Alves E, Almeida AM, Barbosa DBV, Santos AS et al. Doença hepatica gordurosa não alcoólica: características clínicas e histológicas em obesos graves submetidos a cirurgia bariátrica. Acta Gastroenterol Latinoam 2007;37:224-30.
18. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis 2011;31:128-46.
19. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Diseases 2002;34:204-11.
20. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012;53:190-7.
21. Wenk KS, Arrington KC, Erlich A. Psoriasis and nonalcoholic fatty liver disease, J Eur Acad Dermatol Venereol 2011;25:383-91.
22. Campanati A, Ganzetti G, Sario AD, Damiani A, Sandroni L, Rosa L, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2012 Oct 13, E-pub before print.
23. Miele L, Vallone S, Cefalo C. Prevalence, characteristics, and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:778-86.
24. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol 2012;11:5-10.
25. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol 2010;24:1371-7.